Septem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 4140.22%
- Profit Growth 19904.36%
- Ebitda 51.77%
- Net Worth 459.42%
- Total Assets 183.64%
About Septem Pharmaceuticals
Septem Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 April 2018 (Six years and nine months 23 days old ). Its registered office is in Lucknow, Uttar Pradesh.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Meraj Ahmad and Suhail Ahmad serve as directors at the Company.
Company Details
- Location Lucknow, Uttar Pradesh
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24304UP2018PTC103674
-
Company No.
103674
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Apr 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Septem Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meraj Ahmad
|
Director | 26-Apr-2018 | Current |
|
Suhail Ahmad
|
Director | 26-Apr-2018 | Current |
Financial Performance of Septem Pharmaceuticals.
Septem Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 4140.22% increase. The company also saw a substantial improvement in profitability, with a 19904.36% increase in profit. The company's net worth Soared by an impressive increase of 459.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Septem Pharmaceuticals?
Unlock access to Septem Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Septem Healthcare LlpMeraj Ahmad and Suhail Ahmad are mutual person
-
Tricent Pharmaceuticals Private Limited
Meraj Ahmad is a mutual person
-
Tahira Hospitals Private Limited
Suhail Ahmad is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Septem Pharmaceuticals?
Unlock and access historical data on people associated with Septem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Septem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Septem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.